Deals & M&A
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Sweden’s Egetis Catches The Eye Of Suitors
With an EU submission imminent for its MCT8 deficiency therapy Emcitate, Egetis is in talks with “certain external partners” about an acquisition.
EIP And Diffusion Combine To Form CNS Firm With Dementia Focus
The US biotechs are joining forces to form a new, listed company with sufficient cash to advance EIP’s potentially disease-modifying drug candidate through Phase II development in dementia with Lewy bodies, which presents a high unmet need.
Asia Deal Watch: Junshi, Rxilient Form Joint Venture Around Toripalimab
Plus deals involving Biorchestra, Takeda/F-star, TaiGen/Joincare, Dr Reddy’s/Eris, Kaken/bitBiome, CJ Bioscience/4D Pharma, Ono/Macomics, Daiichi Sankyo/Zymeworks, Celltrion/Genuv and more.
GSK Boosts Its Infectious Disease Portfolio With Brexafemme License
The pharma licensed global rights to Scynexis’s Brexafemme, a first-in-class triterpenoid antifungal approved for treat and prevent recurrence of vaginal yeast infections, for $90m up front.
Roche Continues To Cast Its Collaborations Net Wide
The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.
Celltrion Eyes M&A, Global Expansion And Novel Drugs As Founder Returns
Celltrion founder and chairman Jung Jin Seo has outlined why he has decided to return to the Korean biosimilars major and the business priorities for the group if it is to emerge as a top-tier global biopharma operation.
Deal Watch: Vertex Calls On CRISPR Yet Again, Now To Collaborate On Type 1 Diabetes
Vertex and CRISPR look beyond beta thalassemia and sickle cell disease. Also, Bicycle gets $50m up front in Novartis deal, Regeneron commits $75m initially under a Treg collaboration with Sonoma, and Jounce gets a better deal from Concentra to wave off Redx merger.
Pfizer Returns Bavencio Rights To Merck KGaA, Closing An IO Era
The arrangement ends a nearly 10-year collaboration between Pfizer and Merk KGaA on the PD-L1 inhibitor that, despite some success, never reached its ultimate goal.
Stock Watch: Sanofi, Pfizer And The Aftermath Of Acquisitions
Acquisitions usually depress the stock price of the buyer to reflect the dilution and propel the shares of the acquired to reflect the premium. But not always.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: ripples from SVB’s failure; Karuna’s schizophrenia win; big pharma remains open to partnering; ChatGPT comes to medical congresses; and China’s COVID vaccine lessons.
Gilead Waives Acquisition Option As Pionyr Explores Other Strategies
Gilead has waived its option to acquire Pionyr, allowing the US biotech to explore other partnerships and financing opportunities as it advances a promising pipeline of macrophage-targeting antibodies.
Generation Bio’s LNP DNA-Delivery Platform Gets Big Boost From Moderna
The company aims to deliver DNA via lipid nanoparticles as well as delivering LNPs systemically to tissues beyond the liver and spleen, which the CEO called a “frontier” in an interview.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.